Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective hard but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past several shares of mine. The first CytoDyn article of mine, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set away the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire interview that I came away with an inadequate impression of the business.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this know-how and also associated intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) along with the first brand new drug application endorsement ($5 million), and also royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and multiple indications, it has this single treatment as well as a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple delivering presentations in addition to multiple publications.

Can it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the really start of the interest of mine in this particular organization. Judging with the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this question.

CytoDyn is a classic battleground, or maybe some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *